•           CEO Dr Jackie Fairley presenting at the Nomura Biotech Conference for institutional investors in Sydney, 24th July 2012.

•           Presentation to include update on the rapidly advancing VivaGel^® Bacterial Vaginosis Program, and advancements in Drug Delivery and Agrochemicals Programs.

View presentation here

Starpharma today provided an update on the developments within its substantial drug delivery program.

Key Points:

>    Dendrimer-docetaxel program advancing rapidly; clinical trial expected to commence in 2013

>    Successful application of dendrimers to a number of important classes of drugs including small molecules, antibodies and proteins

>    Analysis shows Starpharma’s dendrimers applicable to more than 50% of top-selling pharmaceuticals - highlighting versatility and potential to develop improved formulations

Herald Sun Business Journalist John Beveridge examines Starpharma’s success in reaching commercial milestones and recruiting participants for its VivaGel trials in his In the Black column.

‘Three pivotal clinical trials are now almost completely stocked with test subjects, primarily to check the effectiveness of Starpharma's VivaGel at preventing and treating the common disorder bacterial vaginosis.

These trials are at the very sharp end of proceedings - phase two and phase three before the US Food and Drug Administration - and results should be in before Christmas.

That puts Starpharma chief executive Dr Jackie Fairley in a strong position to negotiate a lucrative deal next year with a large pharmaceutical partner to add marketing and distribution muscle to some excellent Australian-developed science.’

Go to the article (external link)

• Recruitment 100% complete for VivaGel^® Phase 2 prevention study for bacterial vaginosis (BV)
• Recruitment for two pivotal Phase 3 BV treatment studies proceeding rapidly with enrolment of the first trial now 100% complete
• Phase 3 treatment trials and the Phase 2 prevention trial all expected to complete in 2H CY2012.
• Activities to support NDA submission, including manufacturing scale up and validation, well advanced

Key points

• > Enrolment passes 60% for VivaGel^® Phase 3 BV treatment trials
• > Trials well on track for completion in 2012
• > One of the trials has already enrolled more than 80% of subjects

BRW Journalist Tony Featherstone profiled Starpharma as the #1 pick of the leading ASX tech stocks in his article, ‘9 hot tech stocks.

The Melbourne-based company is leading a pack of promising biotechs either in, or approaching, phase III trials for US Food and Drug Administration approval. Starpharma’s lead product, VivaGel, is being developed to treat bacterial vaginosis, where the normal balance of bacteria in the vagina is disrupted by an overgrowth of certain bacteria. If approved, VivaGel, a prescription product, would be applied daily to treat bacteria vaginosis and stop it reoccurring.

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Wednesday 30^th May 2012. Ticky discussed Starpharma’s valuable platform technology.

 Read the Transcript (external link)

Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 31 March 2012.

In this issue:

› Starpharma commences pivotal phase 3 VivaGel^® BV treatment trials

› Starpharma continues to build momentum as a leader in the sector

› Starpharma improves efficacy of leading chemotherapy drug docetaxel with dendrimers in breast cancer model

› Nanobiotechnology to reach $6 billion by 2017

Download: Shareholder Update: April 2012 ( pdf file, 1MB)

Jackie Fairley, CEO, talks to BRR Media on the commencement of two concurrent pivotal phase 3 clinical trials of VivaGel® for the treatment of bacterial vaginosis (BV), following receipt of ethics approval.

Listen to the BRR Broadcast (external link)